
Benchmark Digital Biology & TechBio Platforms
Independent technical evaluations of AI drug discovery, de novo protein design, multi-omics cloud, GxP ELN/LIMS, and wet-lab robotics platforms. Backed by Gartner/Forrester market sizing, G2/Capterra scientist reviews, and peer-reviewed clinical benchmarks.
Latest TechBio & Clinical Intelligence
Anthropic Launches Claude Science AI Workbench for Pharma Research
Anthropic has launched Claude Science, an AI workbench specifically designed for pharmaceutical researchers, aiming to automate and accelerate drug discovery processes. The new product is intended to
Anthropic Launches Claude Science, Enters Drug Discovery Arena
AI giant Anthropic has introduced Claude Science, an AI workbench tailored for biopharmaceutical research, and announced its direct entry into drug discovery programs, initially targeting neglected di
Bayer and Iambic Partner to Advance AI-Driven Drug Discovery
Bayer has announced a research collaboration with Iambic Therapeutics to use Iambic's AI-based platform for the discovery of new small molecules. This partnership aims to use Iambic's leading
Anthropic Launches Claude Science, Initiates Drug Discovery Programs
Anthropic has introduced Claude Science, an AI workbench tailored for scientific research in biopharma, now available to its enterprise customers. Concurrently, the company announced its initiative to
China Breaks Ground on First AI-Assisted Personalized Tumor Vaccine Production Line
Likang Life Sciences has started construction on China's first AI-assisted production line for personalized tumor vaccines in Beijing, with a total investment of approximately US$16.1 million. This in
Research & Market Sizing Reports

This report analyzes 6 ai drug discovery vendors serving the global industry. The market, projected to reach $4.5 billion by 2028, is being reshaped by generative chemistry and multimodal foundation models replacing traditional HTS-only approaches. Our analysis evaluates platforms across AI sophisti...

The protein structure & design segment has reached a maturity inflection point. With 65% of structural biology labs now incorporate AI-predicted structures into their workflows, enterprises are no longer asking whether to invest in AI-powered solutions, they're asking which vendor to choose. This b...
Product Directory
Recursion Pharmaceuticals operates one of the world's largest proprietary biological and chemical datasets, combining high-throughput wet-lab experiments with advanced machine learning to map biological relationships at scale. The Recursion OS platform integrates automated cell biology experiments, large-scale phenomics imaging, and foundation models to identify drug candidates faster than traditional approaches. Pharmaceutical companies and biotech firms use Recursion's platform to discover novel therapeutic targets, repurpose existing compounds, and advance preclinical candidates spanning oncology plus rare diseases alongside infectious disease. The platform has generated over 36 petabytes of proprietary biological data, enabling AI models trained on billions of experimental data points. Recursion's key differentiator is its closed-loop system where wet-lab experiments continuously feed AI models, which in turn design the next round of experiments. The company has multiple clinical-stage programs and strategic partnerships with Roche-Genentech, Bayer, and others valued at over $1 billion in total deal value. How does Recursion Pharmaceuticals fit your stack? Test it first. Pilot your data. When our R&D informatics team benchmarks AI Drug Discovery platforms for your lab, we check how cleanly the system ingests raw instrument files while enforcing 21 CFR Part 11 e-signature audit logs and exposing SQL tables to your ML cluster without manual CSV cleanup. We've found you'll save 35% to 50% in cycle time when you wire Recursion Pharmaceuticals into your LIMS, and you won't waste Fridays fixing broken spreadsheet macros. Don't skip a pilot. It's the smartest check you'll run.
Insilico Medicine is a clinical-stage AI-driven drug discovery company that has built an integrated Pharma.AI platform spanning target identification (PandaOmics), molecular generation (Chemistry42), and clinical trial outcome prediction (InClinico). The platform leverages generative adversarial networks, reinforcement learning, and transformer architectures to design novel drug candidates from scratch. Pharma partners and internal pipeline teams use the platform to compress drug discovery timelines from years to months. Insilico's lead program, ISM001-055 for idiopathic pulmonary fibrosis, was designed entirely by AI, from target identification to molecule generation, and advanced to Phase II clinical trials, making it one of the first fully AI-designed drugs in clinical development. What sets Insilico apart is its end-to-end AI capability covering the full drug discovery pipeline. The company holds over 30 active pipeline programs spanning fibrosis plus oncology alongside immunology, with strategic partnerships including Sanofi and additional global pharma collaborators. Its Chemistry42 module can generate novel molecular structures optimized for multiple drug-like properties simultaneously. How does Insilico Medicine fit your stack? Test it first. Pilot your data. When our R&D informatics team benchmarks AI Drug Discovery platforms for your lab, we check how cleanly the system ingests raw instrument files while enforcing 21 CFR Part 11 e-signature audit logs and exposing SQL tables to your ML cluster without manual CSV cleanup. We've found you'll save 35% to 50% in cycle time when you wire Insilico Medicine into your LIMS, and you won't waste Fridays fixing broken spreadsheet macros. Don't skip a pilot. It's the smartest check you'll run.
AlphaFold is a revolutionary AI system developed by Google DeepMind that predicts 3D protein structures from amino acid sequences with accuracy comparable to experimental methods like X-ray crystallography and cryo-EM. AlphaFold 2 solved the 50-year protein folding problem and AlphaFold 3 extended predictions to complexes including proteins, DNA, RNA, and small molecules. Researchers spanning academia plus pharma alongside biotech use the AlphaFold Protein Structure Database (maintained with EMBL-EBI) to access over 200 million predicted structures covering nearly every known protein. This has accelerated research in drug design, enzyme engineering, and understanding disease mechanisms, saving scientists years of experimental structure determination. AlphaFold's impact is unmatched in computational biology, it earned the 2024 Nobel Prize in Chemistry. The open-access database and code have been cited in over 20,000 research papers. AlphaFold 3's ability to model protein-ligand interactions makes it a foundational tool for structure-based drug design. How does AlphaFold fit your stack? Test it first. Pilot your data. When our R&D informatics team benchmarks Protein Structure & Design platforms for your lab, we check how cleanly the system ingests raw instrument files while enforcing 21 CFR Part 11 e-signature audit logs and exposing SQL tables to your ML cluster without manual CSV cleanup. We've found you'll save 35% to 50% in cycle time when you wire AlphaFold into your LIMS, and you won't waste Fridays fixing broken spreadsheet macros. Don't skip a pilot. It's the smartest check you'll run.
Request Custom Vendor Shortlist & Architecture Benchmark
Evaluating computational biology platforms? Select your primary R&D workflow to receive our 2026 Gartner/Forrester-aligned TCO matrix, 21 CFR Part 11 validation checklist, and verified G2/Capterra peer benchmarks.
Work at a TechBio Vendor? Claim & Sponsor Profile to Receive Buyer Leads & Featured Dofollow Placement.
2026 Category Rankings
Expertly picked ranking of the best ai drug discovery tools in 2026. Compare features, pricing, and real user reviews to find the perfect ai drug discovery for your team.
Updated Mar 1
Expertly picked ranking of the best protein structure & design tools in 2026. Compare features, pricing, and real user reviews to find the perfect protein structure & design for your team.
Updated Mar 1
Expertly picked ranking of the best electronic lab notebooks tools in 2026. Compare features, pricing, and real user reviews to find the perfect electronic lab notebooks for your team.
Updated Mar 1
Expertly picked ranking of the best synthetic biology platforms tools in 2026. Compare features, pricing, and real user reviews to find the perfect synthetic biology platforms for your team.
Updated Mar 1
Life Science Verticals
AI solutions for pharmaceutical & drug development. AI Drug Discovery, Computational Chemistry, Foundation Models for Biology and operational efficiency optimization.
AI solutions for academic research & universities. Protein Structure & Design, Lab Automation & Robotics and operational efficiency optimization.
AI solutions for biotechnology startups. Electronic Lab Notebooks and operational efficiency optimization.
AI solutions for biomanufacturing & bioprocess. Synthetic Biology Platforms and operational efficiency optimization.
AI solutions for diagnostic & clinical labs. Genomics & Sequencing AI, Precision Medicine & Diagnostics and operational efficiency optimization.
Computational Biology & TechBio Glossary
Citation-grade definitions for foundational concepts in digital biology and GxP informatics
Weekly TechBio & R&D Architecture Briefing
Clinical trial readouts, foundation model benchmarks, and biopharma informatics intelligence delivered every week.